This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Glipizide and Metformin Hydrochloride

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20221012

Version

6

Spl Product Data Elements

Glipizide and Metformin Hydrochloride Glipizide and Metformin Hydrochloride GLIPIZIDE GLIPIZIDE METFORMIN HYDROCHLORIDE METFORMIN CROSCARMELLOSE SODIUM HYPROMELLOSES MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE POLYETHYLENE GLYCOL, UNSPECIFIED POVIDONE TITANIUM DIOXIDE FERRIC OXIDE RED PINK CAPSULE ZE68 Glipizide and Metformin Hydrochloride Glipizide and Metformin Hydrochloride GLIPIZIDE GLIPIZIDE METFORMIN HYDROCHLORIDE METFORMIN CROSCARMELLOSE SODIUM HYPROMELLOSES MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE POLYETHYLENE GLYCOL, UNSPECIFIED POVIDONE TITANIUM DIOXIDE POLYSORBATE 80 WHITE CAPSULE ZE67 Glipizide and Metformin Hydrochloride Glipizide and Metformin Hydrochloride GLIPIZIDE GLIPIZIDE METFORMIN HYDROCHLORIDE METFORMIN CELLULOSE, MICROCRYSTALLINE CROSCARMELLOSE SODIUM FERRIC OXIDE RED HYPROMELLOSES MAGNESIUM STEARATE POLYETHYLENE GLYCOL, UNSPECIFIED POVIDONE TITANIUM DIOXIDE PINK CAPSULE ZE66

Application Number

ANDA078905

Brand Name

Glipizide and Metformin Hydrochloride

Generic Name

Glipizide and Metformin Hydrochloride

Product Ndc

65841-659

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-659-01 in bottle of 100 tablets Glipizide and Metformin Hydrochloride Tablets USP, 2.5 mg/250 mg R x only 100 tablets NDC 65841-660-01 in bottle of 100 tablets Glipizide and Metformin Hydrochloride Tablets USP, 2.5 mg/500 mg R x only 100 tablets NDC 65841-661-01 in bottle of 100 tablets Glipizide and Metformin Hydrochloride Tablets USP, 5 mg/500 mg R x only 100 tablets Glipizide and Metformin HCL Tablets Glipizide and metformin HCL Tablets Glipizide and metformin HCL Tablets

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.